Atlas Trials

Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma

Clinical trial NCT03918252 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT03918252
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Mesothelioma
Start date
2019-10-02
Primary completion
2027-06-01
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.